The oncolytic adenovirus TILT-123 co-expresses IL-2 and TNF-α, promotes tumour infiltrating lymphocyte activation[95] and is entering a phase 1 trial for patients with solid tumours (NCT04695327). This evidence concerns the gene IL2 and neoplasm.